---
document_datetime: 2025-12-02 05:46:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/capecitabine-medac.html
document_name: capecitabine-medac.html
version: success
processing_time: 0.1461087
conversion_datetime: 2025-12-26 17:42:08.553166
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Capecitabine Medac

[RSS](/en/individual-human-medicine.xml/65755)

##### Authorised

This medicine is authorised for use in the European Union

capecitabine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Capecitabine Medac](#news-on)
- [More information on Capecitabine Medac](#more-information-on-capecitabine-medac-1081)
- [More information on Capecitabine Medac](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Capecitabine medac is a cancer medicine that is used to treat:

- colon (large bowel) cancer. Capecitabine medac is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes' stage C colon cancer;
- metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body). Capecitabine medac is used on its own or with other cancer medicines;
- advanced gastric (stomach) cancer. Capecitabine medac is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin;
- locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body). Capecitabine medac is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed. It can also be used on its own when treatment with both anthracyclines and taxanes (another type of cancer medicine) has failed or when further treatment with anthracyclines is not suitable for the patient.

Capecitabine medac is a 'generic' and a 'hybrid' medicine. This means that it is similar to a 'reference medicine', but it contains capecitabine at a new strength in addition to existing strengths. While the reference medicine, Xeloda, is available as 150 and 500 mg tablets, Capecitabine medac is also available as 300 mg tablets.

Capecitabine medac contains the active substance capecitabine.

Expand section

Collapse section

## How is Capecitabine medac used?

Capecitabine medac should only be prescribed by a doctor who is qualified in the use of cancer medicines.

Before starting treatment, it is recommended that patients are tested to check that they have a working dihydropyrimidine dehydrogenase ( DPD) enzyme.

Capecitabine medac is available as tablets (150, 300 and 500 mg). The dose depends on the patient's height and weight and the type of cancer being treated. Capecitabine medac tablets should be taken within 30 minutes after a meal. The tablets are given twice daily for 14 days followed by a 7-day gap before the next course.

Treatment is continued for six months after colon surgery. For other types of cancer, treatment is stopped if the disease gets worse or the side effects are unacceptable. Doses need to be adjusted for patients with liver or kidney disease and for patients who develop certain side effects. For patients with partial DPD deficiency, a lower starting dose may be considered.

For more information about using Capecitabine medac, see the package leaflet or contact your doctor or pharmacist.

## How does Capecitabine medac work?

The active substance in Capecitabine medac, capecitabine, is a cytotoxic medicine (a medicine that kills rapidly dividing cells, such as cancer cells) that belongs to the group 'anti-metabolites'. Capecitabine is converted to the medicine fluorouracil in the body, but more is converted in tumour cells than in normal tissues.

Fluorouracil is very similar to pyrimidine. Pyrimidine is part of the genetic material of cells (DNA and RNA). In the body, fluorouracil takes the place of pyrimidine and interferes with the enzymes involved in making new DNA. As a result, it stops the growth of tumour cells and eventually kills them.

## How has Capecitabine medac been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Xeloda, and do not need to be repeated for Capecitabine medac.

As for every medicine, the company provided studies on the quality of Capecitabine medac. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Capecitabine medac?

Because Capecitabine medac is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Capecitabine medac authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Capecitabine medac has been shown to have comparable quality and to be bioequivalent to Xeloda. Therefore, the Agency's view was that, as for Xeloda, the benefits of Capecitabine medac outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Capecitabine medac?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Capecitabine medac have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Capecitabine medac are continuously monitored. Side effects reported with Capecitabine medac are carefully evaluated and any necessary action taken to protect patients.

## Other information about Capecitabine medac

Capecitabine medac received a marketing authorisation valid throughout the European Union on 19 November 2012.

Capecitabine Medac : EPAR - Medicine overview

Reference Number: EMA/372533/2020

English (EN) (188.79 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 05/08/2020

[View](/en/documents/overview/capecitabine-medac-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-318)

български (BG) (212.13 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/bg/documents/overview/capecitabine-medac-epar-medicine-overview_bg.pdf)

español (ES) (176.1 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/es/documents/overview/capecitabine-medac-epar-medicine-overview_es.pdf)

čeština (CS) (212.18 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/cs/documents/overview/capecitabine-medac-epar-medicine-overview_cs.pdf)

dansk (DA) (188.3 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/da/documents/overview/capecitabine-medac-epar-medicine-overview_da.pdf)

Deutsch (DE) (192.51 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/de/documents/overview/capecitabine-medac-epar-medicine-overview_de.pdf)

eesti keel (ET) (175.75 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/et/documents/overview/capecitabine-medac-epar-medicine-overview_et.pdf)

ελληνικά (EL) (216.88 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/el/documents/overview/capecitabine-medac-epar-medicine-overview_el.pdf)

français (FR) (189.4 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/fr/documents/overview/capecitabine-medac-epar-medicine-overview_fr.pdf)

hrvatski (HR) (207.84 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/hr/documents/overview/capecitabine-medac-epar-medicine-overview_hr.pdf)

italiano (IT) (186.31 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/it/documents/overview/capecitabine-medac-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (209.46 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/lv/documents/overview/capecitabine-medac-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (209.07 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/lt/documents/overview/capecitabine-medac-epar-medicine-overview_lt.pdf)

magyar (HU) (208.53 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/hu/documents/overview/capecitabine-medac-epar-medicine-overview_hu.pdf)

Malti (MT) (211.37 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/mt/documents/overview/capecitabine-medac-epar-medicine-overview_mt.pdf)

Nederlands (NL) (189.37 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/nl/documents/overview/capecitabine-medac-epar-medicine-overview_nl.pdf)

polski (PL) (212.98 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/pl/documents/overview/capecitabine-medac-epar-medicine-overview_pl.pdf)

português (PT) (187.97 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/pt/documents/overview/capecitabine-medac-epar-medicine-overview_pt.pdf)

română (RO) (208.34 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/ro/documents/overview/capecitabine-medac-epar-medicine-overview_ro.pdf)

slovenčina (SK) (210.38 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/sk/documents/overview/capecitabine-medac-epar-medicine-overview_sk.pdf)

slovenščina (SL) (207.63 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/sl/documents/overview/capecitabine-medac-epar-medicine-overview_sl.pdf)

Suomi (FI) (185.4 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/fi/documents/overview/capecitabine-medac-epar-medicine-overview_fi.pdf)

svenska (SV) (186.56 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

05/08/2020

[View](/sv/documents/overview/capecitabine-medac-epar-medicine-overview_sv.pdf)

## Product information

Capecitabine Medac : EPAR - Product Information

English (EN) (308.4 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 02/05/2025

[View](/en/documents/product-information/capecitabine-medac-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-386)

български (BG) (646.32 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/bg/documents/product-information/capecitabine-medac-epar-product-information_bg.pdf)

español (ES) (374.03 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/es/documents/product-information/capecitabine-medac-epar-product-information_es.pdf)

čeština (CS) (593.46 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/cs/documents/product-information/capecitabine-medac-epar-product-information_cs.pdf)

dansk (DA) (435.19 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/da/documents/product-information/capecitabine-medac-epar-product-information_da.pdf)

Deutsch (DE) (456.67 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/de/documents/product-information/capecitabine-medac-epar-product-information_de.pdf)

eesti keel (ET) (368.37 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/et/documents/product-information/capecitabine-medac-epar-product-information_et.pdf)

ελληνικά (EL) (654.17 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/el/documents/product-information/capecitabine-medac-epar-product-information_el.pdf)

français (FR) (376.98 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/fr/documents/product-information/capecitabine-medac-epar-product-information_fr.pdf)

hrvatski (HR) (602.15 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/hr/documents/product-information/capecitabine-medac-epar-product-information_hr.pdf)

íslenska (IS) (363.38 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/is/documents/product-information/capecitabine-medac-epar-product-information_is.pdf)

italiano (IT) (450.26 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/it/documents/product-information/capecitabine-medac-epar-product-information_it.pdf)

latviešu valoda (LV) (515.41 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/lv/documents/product-information/capecitabine-medac-epar-product-information_lv.pdf)

lietuvių kalba (LT) (511.55 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/lt/documents/product-information/capecitabine-medac-epar-product-information_lt.pdf)

magyar (HU) (524.57 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/hu/documents/product-information/capecitabine-medac-epar-product-information_hu.pdf)

Malti (MT) (566.59 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/mt/documents/product-information/capecitabine-medac-epar-product-information_mt.pdf)

Nederlands (NL) (350.89 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/nl/documents/product-information/capecitabine-medac-epar-product-information_nl.pdf)

norsk (NO) (349.28 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/no/documents/product-information/capecitabine-medac-epar-product-information_no.pdf)

polski (PL) (531.64 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/pl/documents/product-information/capecitabine-medac-epar-product-information_pl.pdf)

português (PT) (358.14 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/pt/documents/product-information/capecitabine-medac-epar-product-information_pt.pdf)

română (RO) (548.16 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/ro/documents/product-information/capecitabine-medac-epar-product-information_ro.pdf)

slovenčina (SK) (523.17 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/sk/documents/product-information/capecitabine-medac-epar-product-information_sk.pdf)

slovenščina (SL) (538.84 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/sl/documents/product-information/capecitabine-medac-epar-product-information_sl.pdf)

Suomi (FI) (381.12 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/fi/documents/product-information/capecitabine-medac-epar-product-information_fi.pdf)

svenska (SV) (335.45 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

02/05/2025

[View](/sv/documents/product-information/capecitabine-medac-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000531/202404 28/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Capecitabine Medac : EPAR - All Authorised presentations

English (EN) (79.89 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 25/04/2022

[View](/en/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-651)

български (BG) (27.68 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/bg/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_bg.pdf)

español (ES) (7.97 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/es/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_es.pdf)

čeština (CS) (17.25 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/cs/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (7.29 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/da/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (7.53 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/de/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (8.71 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/et/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (28.33 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/el/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_el.pdf)

français (FR) (7.64 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/fr/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (22.93 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/hr/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (7.71 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/is/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_is.pdf)

italiano (IT) (7.54 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/it/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (25.34 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/lv/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.67 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/lt/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (8.21 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/hu/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (23.8 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/mt/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (7.36 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/nl/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (7.57 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/no/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_no.pdf)

polski (PL) (16.35 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/pl/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_pl.pdf)

português (PT) (7.84 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/pt/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_pt.pdf)

română (RO) (19.42 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/ro/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.35 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/sk/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.82 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/sl/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (7.74 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/fi/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (7.55 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

25/04/2022

[View](/sv/documents/all-authorised-presentations/capecitabine-medac-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Capecitabine Medac Active substance capecitabine International non-proprietary name (INN) or common name capecitabine Therapeutic area (MeSH) Colorectal Neoplasms Anatomical therapeutic chemical (ATC) code L01BC06

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes' stage-C) colon cancer.

Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.

Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.

Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

## Authorisation details

EMA product number EMEA/H/C/002568

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

medac Gesellschaft für klinische Spezialpräparate mbH

Theaterstrasse 6

Marketing authorisation issued 19/11/2012 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Capecitabine Medac : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (204.62 KB - PDF)

**First published:** 03/05/2013

**Last updated:** 02/05/2025

[View](/en/documents/procedural-steps-after/capecitabine-medac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Capecitabine Medac-H-C-PSUSA-00000531-202404 : EPAR Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/151502/2025

English (EN) (128.91 KB - PDF)

**First published:** 02/05/2025

[View](/en/documents/scientific-conclusion/capecitabine-medac-h-c-psusa-00000531-202404-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Capecitabine Medac : EPAR - Scientific conclusions

English (EN) (153.51 KB - PDF)

**First published:** 05/08/2020

[View](/en/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_en.pdf)

[Other languages (24)](#file-language-dropdown-87)

български (BG) (153.84 KB - PDF)

**First published:**

05/08/2020

[View](/bg/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_bg.pdf)

español (ES) (151.95 KB - PDF)

**First published:**

05/08/2020

[View](/es/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_es.pdf)

čeština (CS) (160.26 KB - PDF)

**First published:**

05/08/2020

[View](/cs/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_cs.pdf)

dansk (DA) (151.3 KB - PDF)

**First published:**

05/08/2020

[View](/da/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (151.35 KB - PDF)

**First published:**

05/08/2020

[View](/de/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (146.06 KB - PDF)

**First published:**

05/08/2020

[View](/et/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (155.31 KB - PDF)

**First published:**

05/08/2020

[View](/el/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_el.pdf)

français (FR) (155.05 KB - PDF)

**First published:**

05/08/2020

[View](/fr/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (159.55 KB - PDF)

**First published:**

05/08/2020

[View](/hr/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_hr.pdf)

íslenska (IS) (152.16 KB - PDF)

**First published:**

05/08/2020

[View](/is/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_is.pdf)

italiano (IT) (149.57 KB - PDF)

**First published:**

05/08/2020

[View](/it/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (172.71 KB - PDF)

**First published:**

05/08/2020

[View](/lv/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (170.51 KB - PDF)

**First published:**

05/08/2020

[View](/lt/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_lt.pdf)

magyar (HU) (156.62 KB - PDF)

**First published:**

05/08/2020

[View](/hu/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_hu.pdf)

Malti (MT) (179.14 KB - PDF)

**First published:**

05/08/2020

[View](/mt/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (144.7 KB - PDF)

**First published:**

05/08/2020

[View](/nl/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_nl.pdf)

norsk (NO) (141.47 KB - PDF)

**First published:**

05/08/2020

[View](/no/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_no.pdf)

polski (PL) (148.76 KB - PDF)

**First published:**

05/08/2020

[View](/pl/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_pl.pdf)

português (PT) (153.64 KB - PDF)

**First published:**

05/08/2020

[View](/pt/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_pt.pdf)

română (RO) (158.9 KB - PDF)

**First published:**

05/08/2020

[View](/ro/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (167.72 KB - PDF)

**First published:**

05/08/2020

[View](/sk/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (158.32 KB - PDF)

**First published:**

05/08/2020

[View](/sl/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (142.69 KB - PDF)

**First published:**

05/08/2020

[View](/fi/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_fi.pdf)

svenska (SV) (141.88 KB - PDF)

**First published:**

05/08/2020

[View](/sv/documents/scientific-conclusion/capecitabine-medac-epar-scientific-conclusions_sv.pdf)

Capecitabine Medac-H-C-1481-A31-0021 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/274404/2020

English (EN) (983.27 KB - PDF)

**First published:** 05/08/2020

[View](/en/documents/variation-report/capecitabine-medac-h-c-1481-a31-0021-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Capecitabine Medac : EPAR - Public assessment report

Adopted

Reference Number: EMA/711212/2012

English (EN) (249.17 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 29/11/2012

[View](/en/documents/assessment-report/capecitabine-medac-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Capecitabine Medac

Adopted

Reference Number: EMA/CHMP/502040/2012

English (EN) (47.02 KB - PDF)

**First published:** 21/09/2012

**Last updated:** 21/09/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-capecitabine-medac_en.pdf)

#### News on Capecitabine Medac

[EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine](/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine) 30/04/2020

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 March 2020](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-march-2020) 13/03/2020

#### More information on Capecitabine Medac

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Capecitabine Medac

- [Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products - referral](/en/medicines/human/referrals/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products)
- [Xeloda / Capecitabine Accord / Capecitabine Medac / Capecitabine Teva / Ecansya (previously Capecitabine Krka) / Teysuno - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/xeloda-capecitabine-accord-capecitabine-medac-capecitabine-teva-ecansya-previously-capecitabine-krka-teysuno)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/05/2025

## Share this page

[Back to top](#main-content)